Island Pharmaceuticals Readies for ISLA-101 Trial for Dengue Fever

Written By Kathleen Otto

Island Pharmaceuticals is progressing towards a Single Ascending Dose study for its lead asset, ISLA-101, with preparatory work largely complete and key agreements signed. ISLA-101 is a well-known drug candidate that Island is repurposing for the prevention and treatment of dengue and other mosquito borne diseases. 

Kathleen Otto
Previous

Biogen Completes Acquisition of Reata Pharmaceuticals
Next

NORD Partners with Platform Q Health to Provide CME Courses for Healthcare Providers